✦ LIBER ✦

A Phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma

✍ Scribed by Lance Pagliaro; Danai Daliani; Robert Amato; Shi-Ming Tu; Donnah Jones; Terry Smith; Christopher Logothetis; Randall Millikan

Publisher: John Wiley and Sons
Year: 2000
Tongue: English
Weight: 61 KB
Volume: 89
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(20000801)89:3<615::aid-cncr17>3.0.co;2-j

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of subcutaneously adminis

Phase II trial of subcutaneously administered granulocyte-macrophage colony-stimulating factor in patients with metastatic renal cell carcinoma

✍ Edward Wos; Thomas Olencki; Laurie Tuason; G. Thomas Budd; David Peereboom; Kate 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 465 KB 👁 1 views

## BACKGROUND. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a cytokine that is involved in the differentiation and proliferation of various hematopoietic precursors. It also has been reported to enhance the antitumor activity of various mature effector cells. Previous reports have

Phase II trial of 5-fluorouracil, interf

Phase II trial of 5-fluorouracil, interferon-α and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma

✍ Julie A. Ellerhorst; Avishay Sella; Robert J. Amato; Shi-Ming Tu; Randall E. Mil 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 1 views

## RESULTS. Fifty-five patients were enrolled in the trial and 52 were evaluable for ogy, The University of Texas M. D. Anderson response. All patients experienced fever and flu-like symptoms. Grade 3 or 4 nonhe-Cancer Center, Houston, Texas. matologic toxic effects included hypertension (48%), d

Granulocyte-macrophage-colony stimulatin

Granulocyte-macrophage-colony stimulating factor in metastatic renal cell carcinoma : A phase II trial

✍ Brian I. Rini; Walter M. Stadler; Ricardo T. Spielberger; Mark J. Ratain; Nichol 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB 👁 1 views

## BACKGROUND. Due to lack of success with standard chemotherapy and only modest

Granulocyte-macrophage–colony stimulatin

Granulocyte-macrophage–colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma : Results of two Phase II clinical trials

✍ Christopher W. Ryan; Nicholas J. Vogelzang; Mary C. Dumas; Timothy Kuzel; Walter 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 1 views

The aim of this study was to determine the response rates and toxicity of two regimens containing granulocyte-macrophage-colony stimulating factor (GM-CSF) in combination with interleukin-2 (IL-2) in the treatment of patients with metastatic renal cell carcinoma. ## METHODS. Therapy given in the f

A phase II study of constant-infusion fl

A phase II study of constant-infusion floxuridine for the treatment of metastatic renal cell carcinoma

✍ Mary J. Wilkinson; John W. Frye; Eric J. Small; Alan P. Venook; Peter R. Carroll 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 347 KB 👁 1 views

Background. Twenty-nine patients with metastatic renal cell carcinoma (RCC) were treated with constantinfusion floxuridine (FUdR, Roche Laboratories, Nut-Methods. The initial dosage was 0.075 mg/kg/day for 14 days every 28 days and was increased or decreased by 0.025-mg/kg/day increments at each sub

Phase II trial of dimethyltriazenoimidaz

Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid

✍ Ronald M. Bukowski; Catherine M. Tangen; Robert F. Peterson; Thomas R. Fleming; 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 347 KB 👁 1 views

Background. The use of chemotherapy in patients with metastatic carcinoid tumors has been of limited value, and investigiition of new agents is necessary. Previous reports have suggested that dimethyltriazenoimidazole carboxamide (DTIC) may have antitumor activity. Methods. A Phase I1 trial to inve